Table 1.

Clinical implications of non-coding RNAs in perinatal hypoxia ischemia studies: SYMBOLS: ↑, Upregulation; ↓, Downregulation; –, Not specified.

Observed in		Observed effect in HI	Clinical implications	References
Human	Blood plasma	↑miR-210	Therapeutic target	(54)
	Placenta			(55)
			Biomarker	(56)
				(57)
				(58)
	Umbilical cord blood	↓miR-210		(54)
		↓miR-374a		(59)
		↓miR-181b-5p ↓miR-374a-5p ↓miR-376c-3p		(60, 61)
		↓miR-181b		(60, 61)
		↑miR-210
	Maternal whole blood			(55)
Pig	Blood plasma			(58)
Rat	Cerebral cortex		Inhibition of miR-210 as therapy	(62)
				(63)
				(64)
		↓miR-139-5p	miR-139-5p agomir as therapy	(65)
		↓miR-129-5p	miR-129-5p mimic as therapy	(66)
		↓miR-23a/b ↑lncRNA-GAS5	↑miR-23a by ↓GAS5 as therapy	(67)
		↓miR-17	IRE1α RNase inhibitor and miR-17-5p mimic as therapy	(68)
		↓miR-17-5p	PPAR-β/δ agonist GW0742 as therapy	(69)
		↑chr6:48820833|48857932	circRNAs as diagnostic tools and therapeutic targets	(70)
	Hippocampus and cortex	↑lncRNAs BC088414	Inhibition of BC088414 as therapy	(71)
	Hippocampus	↓miR124 ↓miR132 ↓miR134	Maternal tRESV supplementation diet as neuroprotective strategy	(72)
	Pineal gland	↑miR-325-3p	Inhibition of miR-325-3p as therapy	(73)
Mice	Cerebral cortex	↓miR-23a/b ↓miR-27a/b	Therapeutic targets	(74)
		↓miR-592-5p	miR-592-5p upregulation as neuroprotective strategy	(75)
	Hippocampus	↑Meg3	↑miR-129-5p silencing of Meg3 as therapy	(76)
In vitro	OGD-induced activated microglial cells	↓miR-21	Ectopic miR-21 as therapy	(77)

HI, hypoxia-ischemia; miR(NA), micro RNA; PPAR-β/δ, Peroxisome proliferator-activated receptor beta or delta; Procr, endothelial protein C receptor; tRESV, trans resveratrol.